


Practitioner's Docket No. MPI00-408P1RM

PATENT



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent application of: Kapeller-Libermann, Rosana et al.
Application No.: 10/001,227 Group No.: 1647
Filed: November 30, 2001 Examiner: Jon McClelland Lockard
For: METHOD OF USING 18903 TO TREAT PAIN AND PAIN-RELATED DISORDERS.

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

1. The information disclosure statement submitted herewith is being filed:

Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

After three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail. as "Express Mail Post Office to Addressee"
Mailing Label No. _____

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.


Signature

Sean Hunziker

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

03/21/2005 FMETEK11 00000005 501668
10001227
180.00 DA
01 FC:1806

Practitioner's Docket No. MPI00-408P1RM

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

FEE PAYMENT

2. The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

Applicant believes no fee is due in connection with this submission.

Fee due \$0.00

METHOD OF PAYMENT OF FEE

3. Attached is a check in the amount of \$ _____.

Charge Account No. 501668 in the amount of \$180.00

A duplicate of this request is attached.

If any additional fees are due, please charge Account 501668.

March 15, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By Mario Cloutier
Mario Cloutier
Limited Recognition Under 37 C.F.R. §11.9(b)
40 Landsdowne Street
Cambridge, MA 02139
Telephone - 617-577-3522
Facsimile - 617-551-8820



Practitioner's Docket No. MPI00-408P1RM

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: **Kapeller-Libermann, Rosana et al.**
Application No.: **10/001,227** Group No.: **1647**
Filed: **November 30, 2001** Examiner: **Jon McClelland Lockard**
For: **METHOD OF USING 18903 TO TREAT PAIN AND PAIN-RELATED
DISORDERS.**

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. Preliminary Statements;
2. Forms PTO/SB/08A and PTO/SB/08B (substitute for Form PTO-1449);
3. Copies of Listed Information Items Accompanying This Statement (A1-A6, B1-B6, A7-A10)

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

with sufficient postage as first class mail.


37 C.F.R. SECTION 1.10*

as "Express Mail Post Office to Addressee"
Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.

Signature _____


Sean Hunziker

(type or print name of person certifying)

Date: March 15, 2005

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI00-408P1RM

Preliminary statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Copies of Listed Information Items Accompanying This Statement

Legible copies of items listed in Forms PTO/SB/08A and PTO/SB/08B (substitute for Form PTO-1449) accompany this information statement (A1-A6, B1-B6, A7-A10).

March 15, 2005

MILLENNIUM PHARMACEUTICALS, INC.

By: *Mario Cloutier*

Mario Cloutier

Limited Recognition Under 37 C.F.R. §11.9(b)

40 Landsdowne Street

Cambridge, MA 02139

Telephone - 617-577-3522

Facsimile - 617-551-8820

Please type a plus sign (+) inside this box → +

PTO/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		MAR 17 2005 PATENT & TRADEMARK OFFICE U.S. DEPARTMENT OF COMMERCE		<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/001,227
(use as many sheets as necessary)				Filing Date	November 30, 2001
				First Named Inventor	Kapeller-Libermann, Rosana, et al.
				Group Art Unit	1647
				Examiner Name	Jon McClelland Lockard
Sheet	1	of	1	Attorney Docket Number	MPI00-408PIRM

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document (MM-DD-YYYY)	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Kind Code ⁵ Number ⁴ (if known)				
	A1		WO 97/23633	A1	Gistbrocades B.V.	07-03-1997	Entire document
	A2		WO 98/45435	A2	Genetics Institute, Inc.	10-15-1998	SEQ ID 1357 and EST clone CB37, pp 1-92, 543-544, 590-631 & Int'l Search Report
	A3		WO 99/42593	A1	St. Jude Children's Research Hospital	08-26-1999	Entire document
	A4		WO 01/46443	A2	Incyte Genomics, Inc.	06-28-2001	Entire document
	A5		WO 01/94629	A2	Avalon Pharmaceuticals, Inc.	12-13-2001	Entire document
	A6		WO 02/29103	A2	Gene Logic, Inc.	04-11-2002	Entire document

Examiner Signature		Date Considered	

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		(use as many sheets as necessary)	
Sheet	1	of	1
Attorney Docket Number			
OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and-or country where published.	
	B1	Ghosh, Shobha, et al., "Molecular Cloning and Expression of Rat Hepatic Neutral Cholesteryl Ester Hydrolase", <i>Biochimica et Biophysica Acta</i> , Vol. 1259, (December 7, 1995), pp. 305-312.	
	B2	Hwang, Cheng-Shine, et al., "Molecular Cloning and Sequencing of Thioesterase B cDNA and Stimulation of Expression of the Thioesterase B Gene Associated with Hormonal Induction of Peroxisome Proliferation", <i>The Journal of Biological Chemistry</i> , Vol. 268, No. 19, (July 5, 1993), pp. 14278-14284.	
	B3	Medda, S., et al., "The Carboxylesterase Family Exhibits C-Terminal Sequence Diversity Reflecting the Presence or Absence of Endoplasmic-Reticulum-Retention Sequences", <i>The European Journal of Biochemistry</i> , Vol. 206, (June 15, 1992), pp. 801-806.	
	B4	Robbi, Mariette, et al., "Nucleotide Sequence of cDNA Coding for Rat Liver pl 6.1 Esterase (ES-10), a Carboxylesterase Located in the Lumen of the Endoplasmic Reticulum", <i>Biochemistry Journal</i> , Vol. 269, (July 15, 1990), pp. 451-458.	
	B5	Satoh, Tetsuo, et al., "Molecular Aspects of Carboxylesterase Isoforms in Comparison With Other Esterases", <i>Toxicology Letters</i> , (December 1995), 82/83, pp. 439-445.	
	B6	Yamada, T., et al., "Localization of an Isoform of Carboxylesterase in Rat Brain Differs From That in Human Brain", <i>Brain Research</i> , Vol. 674, (March 13, 1995), pp. 175-179.	
	A7	Hwang, C.S., et al., "Fatty Acyl-CoA Hydrolase Precursor, Medium Chain (Thioesterase B)," May 1 2005 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on March 2, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . Swiss Prot Accession No. Q04791.	
	A8	Hillier, L., et al., "zx42h02.r1 Soares_Total_Fetus_Nb2HF8_9w Homo Sapiens cDNA Clone IMAGE: 789171 5' Similar to TR:G1931 G1931 Carboxylesterase Precursor ;, mRNA Sequence" June 4, 1997 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on March 2, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AA450272.	
	A9	Robbi, M., et al., "Liver Carboxylesterase 10 Precursor (Carboxyesterase ES-10) (PI 6.1 Esterase) (ES-HVEL)," October 25, 2004 (sequence) GenPept [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on March 2, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . Swiss Prot Accession No. P16303.	
	A10	Stausberg, Robert, "xu54ell.x1 NCI_CGAP_Ut1 Homo Sapiens cDNA Clone IMAGE:2805548 3' Similar to SW:ES10-RAT P16303 Liver Carboxylesterase 10 Precursor ;, mRNA Sequence," March 3, 2000 (sequence) GenBank [online] Bethesda, MD, USA: National Center for Biotechnology Information [retrieved on March 2, 2005]. Retrieved from the Internet: URL: http://www.ncbi.nlm.nih.gov/ . GenBank Accession No. AW512144.	

Examiner Signature		Date Considered
--------------------	--	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.